In Japan, drug-eluting stents (DES) were introduced in September 2004. The aim of the present study was to clarify how DES affected the proportions of percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG) procedures performed in Japan. Conclusions: There has been marked expansion of PCI and a gradual increase in off-pump CABG after the introduction of DES. It is essential to establish guidelines in Japan for a consensus between cardiologists and cardiovascular surgeons on evidence-based best practice. (Circ J 2010; 74: 1635 - 1643 
he past few decades have witnessed marked technological innovation in the treatment of coronary artery diseases (CAD). Since coronary artery bypass grafting (CABG) was first described in 1968, 1 its postoperative and long-term outcomes have been markedly improved due to advancements in minimally invasive techniques coupled with enhanced myocardial preservation, graft harvesting, off-pump methodology and more sophisticated perioperative management. 2 
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In the late 1970s the introduction of percutaneous coronary intervention (PCI) with ordinary balloon angioplasty (POBA) offered an alternative choice of treatment to CABG. 3 Since then, comparisons between CABG and PCI with regard to postoperative complications, long-term mortality, and revascularization rate have attracted much clinical interest and debate, leading to a number of rigorous clinical trials. 4, 5 Because of the rapid technological innovations, however, timely evaluation of treatment strategies for CAD has been essential, yet it is a difficult undertaking.
The development of new PCI devices during the 1990s made it possible to treat more complex lesions and a wider range of patients. 6,7 Bare metal stents (BMS) became the most popular alternative to CABG because of their effectiveness in preventing acute occlusion and the marked reduction in the revascularization rate compared with POBA. 8, 9 Further advancement has occurred due to the introduction of drug-eluting stents (DES). The US Food and Drug Administration (FDA) approved the sirolimus-eluting stent in 2003 and the paclitaxel-eluting stent in 2004, based on the results of randomized controlled clinical trials that indicated a reduction in target-vessel revascularization compared with HORIGUCHI H et al.
BMS. 10,11
In Japan, the sirolimus-eluting stent was approved for use under the national insurance reimbursement scheme in September 2004.
Although the therapeutic effectiveness of these alternatives is still under scientific evaluation, 12-15 cardiologists quickly and enthusiastically embraced DES after authority approval, and millions of DES have already been implanted worldwide. 16 The introduction of DES has been reported to reduce the number of CABG, and to increase the preoperative risk pool of CABG candidates by substituting for CABG in patients with mild -moderate operative risks. 17, 18 Others also claimed that the substitution of DES for CABG was not necessarily determined only by clinical indications, but also by non-scientific reasons such as hospital ownership and payment structures. 19 The actual increase in DES use, however, and its impact on the clinical practices in CAD in a nationwide setting remain unclear in Japan, the second largest market for DES in the world.
The purpose of the present survey was therefore to determine the trend of various therapeutic options for CAD including conservative therapy, PCI and CABG between 2004 and 2007 in Japan, and to clarify how DES affected the proportion of PCI and CABG procedures.
Methods

Japanese Reimbursement System
Public medical insurance is a single-payment scheme in Japan. Reimbursement is on a fee-for-service basis following the fee schedule that the government decides every 2 years. Since 2003 the government introduced to acute care hospitals the patient classification system called the Diagnosis Procedure Combination (DPC) and related per-diem reimbursement based on patient mix by DPC. The new reimbursement policy, however, covers hospital fees, and the fees for operation and devices including coronary stent are paid for on a fee-for-service basis. Once a new device is approved for use by the government agency, the national fee schedule decides the reimbursement price.
DPC Database
For the present study we used the Japanese DPC Database, which is a patient discharge and administrative claims database to which the acute care hospitals under the DPC reimbursement policy voluntarily submit. The DPC database is similar to the US Medicare claims database 20 or the US Nationwide Impatient Samples. 21 The DPC survey was conducted between 1 July and 30 October in 2004 and 2005 and has been conducted between 1 July and 31 December since 2006 by the DPC Research Group funded by the Ministry of Health, Labour and Welfare, Japan. In 2007, data from around 3 million inpatients were collected in the database, which represented approximately 45% of all acute care inpatient hospitalizations in Japan. 22, 23 The DPC database can be used to identify, track, and analyze national trends in health-care utilization, access, quality, outcomes, and costs. The database includes the following information: location of hospital; patient age and sex; diagnoses, comorbidities at admission and complications after admission coded with International Classification of Diseases, 10th Revision codes; procedures coded according to the Japanese claim classification (K-codes); drugs and devices used; length of stay (LOS); in-hospital mortality; and costs. The diagnoses are recorded by the physicians in charge with reference to the medical charts.
Because of the anonymous nature of the data, the requirement for informed consent was waived. Study approval was obtained from the institutional review board of the hospital with which the last author was affiliated. Abbreviations see in Table 1 .
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who were admitted only for examination were excluded.
Data
We extracted information on patient age; sex; diagnoses; procedures (PCI without stents; PCI with stents; on-pump CABG; and off-pump CABG); and in-hospital mortality; LOS; and total cost estimated by reference prices in the fee schedule of the national medical insurance. The Charlson comorbidity index was calculated for each patient following the Quan et al algorithm. 24 The number of stents (BMS and/or DES) used was obtained from the database. Patients were categorized into 7 groups: (1) conservative therapy; (2) PCI without stents; (3) PCI with BMS alone; (4) PCI with DES alone; (5) PCI with both BMS and DES; (6) on-pump CABG; and (7) off-pump CABG.
Mean age, gender ratio, and in-hospital mortality were presented for each of the 7 therapeutic alternatives each year. University hospitals were categorized as "teaching hospital", and others were coded as "non-teaching hospital".
Statistical Analysis
Fisher's exact test was used to determine differences in proportions. Analyses of variance were conducted to determine differences in averages. Multi-nominal logistic regression analysis was performed to identify any association between patient age, sex, comorbidities, and hospital teaching status on the therapeutic choice pattern before and after DES introduction. The odds ratio for conducting each therapeutic option compared with conservative therapy was presented. P<0.05 was taken as statistically significant. Statistical analysis was conducted using Stata SE version 10.0 (Stata, College Station, TX, USA).
Results
One hundred and forty-four hospitals (59 teaching and 85 Table 2 lists the 4-year trend in the characteristics of AMI patients for each procedure. Overall in-hospital mortality in 2007 (7.9%) was relatively low compared with that in 2004 (9.0%), but the difference was not significant (P=0.248). The conservative therapy group had the highest mean age (71.4 years) and the highest mortality (19.8%). In the conservative therapy group, in-hospital mortality was relatively low in 2007 (16.5%) compared with that in 2004 (21.6%), but the difference was not significant. (P=0.122). In-hospital mortality following on-pump and off-pump CABG was 17.5% and 4.2%, respectively, although the number of patients was lower than those undergoing PCI and conservative therapy. Figure 3 shows trends stratified by teaching hospital status. A difference was found between teaching and non-teaching hospitals in the change in pattern of therapeutic options over time, specifically in the pattern of CABG. On-pump CABG 
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markedly decreased in teaching hospitals after DES introduction, while the number remained the same in non-teaching hospitals. Off-pump CABG continuously increased over the study period, and the trend was more obvious in teaching hospitals.
The results of multi-nominal logistic regression for the likelihood of interventional treatment use are given in Table 4 . In 2004 before DES introduction, compared with non-teaching hospitals, teaching hospitals were 2-fold more likely to conduct on-pump CABG and 3.6-fold more likely to conduct off-pump CABG, after adjusting for patient age, sex, and Charlson comorbidity index. In 2005, however, the odds ratio of teaching hospital status for conducting on-and off-pump CABG markedly decreased, followed by a rebound increase in 2006. In contrast, teaching hospitals were less likely to use DES by 0.87-0.89-fold compared with nonteaching hospitals throughout the period. The likelihood of using BMS and POBA was not significantly different according to teaching status.
Discussion
To our knowledge the present study is the first to investigate changes in revascularization trends in a nationwide setting in Japan since the introduction of DES. The current study identified marked changes in the therapeutic choices of CAD after the introduction of DES. First, in both AMI and AP patients, the total number of CAD patients treated in hospitals increased, although the number of patients undergoing conservative therapy was stable, suggesting that a larger proportion of CAD patients become eligible for interventional therapies. Second, since its introduction, the proportion of DES procedures quickly expanded among the therapeutic options for CAD. Among AP patients, DES mainly replaced BMS and POBA. Third, and most notably, the number of offpump CABG gradually increased. Moreover, this survey identified a substantial proportion of use of DES for AMI, although the use of DES for AMI remained to be approved in the national insurance scheme. Fourth, multi-nominal logistic regression analysis showed that the pattern of use of therapeutic options was significantly determined by patient characteristics, and also by hospital characteristics such as teaching status. Even after adjusting for age, sex, and comorbidity, the proportion of DES use was greater in non-teaching hospitals than in teaching hospitals, where high-technology medicine was expected to be adopted earlier. In contrast, off-pump CABG was more likely to be conducted in teaching hospitals throughout the study period. CHD, coronary heart disease; ORadj, adjusted odds ratio. Other abbreviations see in Table 1 .
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Before the introduction of DES, the Japanese Coronary Intervention Study Group investigated the change in the therapeutic choice for CAD between 1997 and 2000, and found that the ratio of PCI to CABG did not change, while the number of PCI and CABG conducted increased by 1.3-fold during the 3 years. The authors attributed this to then new technology such as BMS and generous reimbursement in Japan. 25 As the current survey showed, the extension of DES use was observed concurrently with the increase in number and proportion of patients undergoing interventional therapy as a whole. Thus, it was suspected that the introduction of DES not only replaced existing PCI, but also increased a patient's eligibility for PCI.
The situation, however, may be different between teaching hospitals and non-teaching hospitals. As Table 4 shows, teaching hospitals were less likely to conduct DES and more likely to conduct off-pump CABG compared to their nonteaching counterparts, after adjusting for patient age and comorbidity. Thus, the 2 groups had distinct practice patterns. A high ratio of PCI to CABG is a unique characteristic in Japanese coronary intervention, 25 and it is speculatively attributed to Japanese culture, which favors less invasive techniques, especially for elderly patients with fragility. 26 PCI with DES and off-pump CABG are regarded as high-tech less-invasive techniques. Because off-pump CABG requires very skilled technique and complex equipment, 26 and teaching hospitals can better afford ample human resource to maintain them, DES may be a more cost-effective choice for non-teaching hospitals. Several trials comparing CABG and PCI involving stents in patients with multivessel disease have found similar survival rates but higher revascularization rates among patients with stents. 8,12,27 Pivotal randomized trials of DES compared with BMS have shown significant reductions in the rate of repeat intervention, with similar rates of death and myocardial infarction. 10,11 Studies comparing CABG and PCI involving DES showed that the rates of death and myocardial infarction were similar. 28, 29 The remarkable clinical efficacy of DES has led to further extended use of this device in patients with more complex coronary anatomical features, for example left main truncus, 30 and/or with higher risk of revascularization, such as diabetics. 31 The most recent guidelines for PCI by the American College of Cardiology/American Heart Association/Society for Cardiovascular Angiography and Interventions have taken into account the rapid change in therapeutic technology and scientific evaluation in this area, and have revised several recommendations: for example primary use of DES in AMI was upgraded in clinical recommendation levels from class IIb to class IIa. 32 It should be noted that DES use for AMI was observed in approximately one-fifth of cases in participating hospitals in our dataset. Again, a difference was observed with teaching status: the number exceeded 25% in non-teaching hospitals, while it was below 20% in teaching hospitals. Because of the lack of detailed information on diseased vessels in the present dataset, we could not provide descriptive statistics on off-label use for anatomically complex lesions such as left main truncus and bifurcation. As reports from the USA and other countries have also mentioned, off-label use of DES occurred in a not-insignificant proportion of patients before this was justified by rigorous scientific evaluation through randomized clinical trials. 33- 35 Marroquin et al, analyzing observational registry data, reported that off-label use of DES was not associated with an increased risk of death or myocardial infarction at 1 year, as compared with BMS, although longer observation would be needed to confirm the relative benefit of DES use over BMS and other treatment alternatives. 33 After authority approval, DES use rapidly became widespread worldwide, as occurred in Japan. Because coronary stent is paid on a fee-for-service basis in Japan, once the reimbursement policy approved DES, it rapidly spread in the Japanese market, as we saw in our analysis. In March 2007, safety concerns regarding late thrombosis of DES arose, 16 which caused deceleration of DES use worldwide. A similar pattern, however, was not clearly identified in the present study. The continuous increase in the DES use observed in Japan may not be attributed solely to the generous reimbursement system and but also to other factors such as practice norms among interventionists, which would need further investigation.
Taking these observations into consideration, we discuss several aspects of the past trend and future goal for therapeutic approaches in CAD. The present study and previous reports from other countries suggest that PCI and CABG are complementary, not competitive, but their roles as treatment alternatives for CAD are evolving as new technology is introduced before formal scientific evaluation of the technology becomes available through clinical trials. The rapid expansion of both on-label and off-label use of innovative technology is inevitable and likely to continue in future, because the real-world use of new technology is dynamic. New technology, however, should be cautiously used with timely empirical evaluation. For this very reason repeated and continual revision of guidelines based on evidence-based studies should be established in Japan to enable open debate and consensus among cardiologists and cardiovascular surgeons as regards best practice for CAD patients.
Several limitations should be acknowledged. The DPC data did not include information on cardiac function, coronary angiographic findings, or the laboratory data that are known to be associated with operative prognosis. Because of this data limitation, the logistic analysis included only patient age, sex, and comorbidity status for risk adjustment. Thus, the difference in status observed across teaching hospitals could be derived from the difference in clinical characteristics of patients in different institutions. Both stable and unstable angina were categorized into the same diagnostic category of AP in the DPC database, and we could not assess the proportion of unstable AP in all AP cases. In addition, the present study included data from only 144 hospitals. Although the present dataset included a majority of university-affiliated hospitals, several institutions with a larger case volume were not included, which would lead to sample selection bias and limit the generalizability of the findings. To allow more valid and timely evaluation, a comprehensive case registry of CAD patients with various therapeutic options, including both PCI and CABG, is urgently required. Finally, seasonal variation may be concerned. The DPC survey was conducted between In conclusion, the current study provided descriptive statistics of the changes in the choices of therapeutic options for CAD treatment after DES introduction. The changing and complementary roles of PCI and CABG for CAD treatment, however, will need ongoing evaluation of clinical effectiveness in the Japanese setting.
